TSHA 8-K: Company announces full rights to TSHA-102 for Rett

Rhea-AI Filing Summary

Taysha Gene Therapies (TSHA) filed a current report stating it issued a press release titled “Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome.”

The press release, dated October 16, 2025, is furnished as Exhibit 99.1 and incorporated by reference. TSHA-102 is described as the company’s lead program under clinical evaluation for Rett syndrome. No additional terms or financial details are included in this excerpt.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001806310 0001806310 2025-10-16 2025-10-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 16, 2025

Taysha Gene Therapies, Inc.

(Exact name of registrant as specified in its Charter)

Delaware		001-39536		84-3199512
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3000 Pegasus Park Drive, Suite 1430 Dallas, Texas		75247
(Address of Principal Executive Offices)		(Zip Code)

(214) 612-0000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value		TSHA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 16, 2025, Taysha Gene Therapies, Inc. issued a press release entitled “Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome.” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated October 16, 2025.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Taysha Gene Therapies, Inc.
				By:		/s/ Kamran Alam
Date: October 16, 2025						Kamran Alam
						Chief Financial Officer

FAQ

What did TSHA (TSHA) announce in this 8-K?

The company issued a press release stating it regained full rights to its lead TSHA-102 program in clinical evaluation for the treatment of Rett syndrome.

When was the press release issued?

The press release is dated October 16, 2025 and is attached as Exhibit 99.1.

Which program is referenced in the announcement?

The announcement references TSHA-102, described as the company’s lead program in clinical evaluation for Rett syndrome.

Where can I find the full details of the announcement?

The full text of the press release is included as Exhibit 99.1 and incorporated by reference.

What exchange lists Taysha Gene Therapies’ common stock?

The company’s common stock trades on The Nasdaq Stock Market LLC under the symbol TSHA.

Does this filing include financial or deal terms?

This excerpt does not include additional terms or financial details beyond the press release reference.